NCT05877053

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

A Phase 1, Double-blind, Randomized, Placebo-controlled, Multi-part, Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Cytokinetics · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purposes of this study are to: * Learn about the safety and tolerability of CK 4021586 after a single dose and multiple doses in healthy subjects. * Find out how much CK-4021586 is in the blood after a single dose and multiple doses. * Determine the effect different doses of CK-4021586 on the pumping function of the heart. * Determine the effect of food in the stomach on how much CK-4021586 is in the blood after a single dose.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	CK-4021586	CK-4021586
DRUG	Placebo for CK-4021586	Placebo for CK-4021586

Timeline

• Start date: 2023-05-09
• Primary completion: 2024-11-20
• Completion: 2024-11-20
• First posted: 2023-05-26
• Last updated: 2025-05-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study